A prospective study of plasma fibrinogen levels and the risk of stroke among participants in the bezafibrate infarction prevention study



      Plasma fibrinogen has emerged as an important predictor of cardiovascular disease, but few data are available on its association with stroke. We sought to determine if plasma fibrinogen is a marker of increased risk or a direct causative risk factor for stroke.

      Subjects and methods

      Patients from the Bezafibrate Infarction Prevention Study, a placebo-controlled, randomized clinical trial of secondary prevention of coronary heart disease by lipid modification with bezafibrate retard (400 mg daily), were studied. Plasma fibrinogen levels were measured at baseline and yearly thereafter. Stroke, a prospectively monitored endpoint, was systematically assessed regarding stroke type, subtype, and functional outcome.


      Mean baseline fibrinogen levels were significantly higher in patients subsequently having a cerebrovascular event (140 strokes, 36 transient ischemic attacks; mean follow-up, 6.2 years) than in patients who did not (375 vs. 349 mg/dL, P <0.0001). Fibrinogen levels did not differ significantly by the type, subtype, or severity of the cerebrovascular event. Risk of ischemic stroke increased from 3.3% in the lowest tertile (baseline fibrinogen <314 mg/dL) to 7.% in the middle tertile (fibrinogen 314 to 373 mg/dL) to 10% in the upper tertile (fibrinogen >373 mg/dL, P <0.001). Adjusting for age, blood pressure, and other covariates, fibrinogen levels in the upper tertile were associated with more than a twofold increase in risk of ischemic stroke compared with in the lowest tertile (hazard ratio = 2.6; 95% confidence interval: 1.5 to 4.3). We did not find fibrinogen change from baseline to be related to subsequent ischemic stroke events.


      Plasma fibrinogen is a strong predictor of, rather than a direct causative factor for, subsequent stroke among patients at increased risk owing to manifest coronary heart disease.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Danesh J
        • Collins R
        • Appleby P
        • et al.
        Association of fibrinogen, C-reactive protein, albumin or leukocyte count with coronary heart disease.
        JAMA. 1998; 279: 1477-1482
        • Maresca G
        • Blasio A.D
        • Marchioli R
        • et al.
        Measuring plasma fibrinogen to predict stroke and myocardial infarction.
        Arterioscler Thromb Vasc Biol. 1999; 19: 1368-1377
        • Ma J
        • Hennekens C.H
        • Ridker P.M
        • et al.
        A prospective study of fibrinogen and risk of myocardial infarction in the physicians’ health study.
        J Am Coll Cardiol. 1999; 33: 1347-1352
        • Resch K.L
        • Ernst E
        • Matrai A
        • et al.
        Fibrinogen and viscosity as risk factors for subsequent cardiovascular events in stroke survivors.
        Ann Intern Med. 1992; 117: 371-375
        • Benderly M
        • Graff E
        • Reicher-Reiss H
        • et al.
        Fibrinogen is a predictor of mortality in coronary heart disease patients.
        Arterioscler Thromb Vasc Biol. 1996; 16: 351-356
        • Stec J.J
        • Silbershatz H.H
        • Tofler J.H
        • et al.
        Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham offspring population.
        Circulation. 2000; 102: 1634-1638
        • Barasch E
        • Benderly M
        • Graff E
        • et al.
        Plasma fibrinogen levels and their correlates in 6457 coronary heart disease patients.
        J Clin Epidemiol. 1995; 48: 757-765
        • Dormandy J
        • Ernst E
        • Matrai A
        • et al.
        Hemorrheologic changes following acute myocardial infarction.
        Am Heart J. 1982; 104: 1364-1367
        • Eisenberg S
        Blood viscosity and fibrinogen concentration following cerebral infarction.
        Circulation. 1966; 33: 10-14
        • Wilhelmsen L
        • Svørdsudd K
        • Korsan-Bengtsen K
        • et al.
        Fibrinogen as a risk factor for stroke and myocardial infarction.
        N Engl J Med. 1984; 311: 501-505
        • Kannel W.B
        • Wolf P.A
        • Castelli W.P
        • et al.
        Fibrinogen and risk of cardiovascular disease. The Framingham Study.
        JAMA. 1987; 258: 1183-1186
        • Folsom A.R
        • Rosamond W.D
        • Shahar E
        • et al.
        Prospective study of markers of hemostatic function with risk of ischemic stroke.
        Circulation. 1999; 100: 736-742
        • BIP Study Group
        Secondary prevention by raising HDL-cholesterol and reducing triglycerides in patients with coronary artery disease.
        Circulation. 2000; 102: 21-27
        • Hemker H.C
        • Kop J
        • Willems G.M
        Kinetic aspects of the interaction of blood clotting enzymes. VIII. The relation between clotting time and clotting velocity.
        Thromb Haemost. 1979; 41: 309-313
        • Adams H.P
        • Bendixen B.H
        • Kappelle L.J
        • et al.
        Classification of subtype of acute ischemic stroke.
        Stroke. 1993; 24: 35-41
        • Van Swieten J.C
        • Koustaal P.J
        • Visser M.C
        • et al.
        Interobserver agreement for the assessment of handicap in stroke patients.
        Stroke. 1988; 19: 604-607
      1. SAS/STAT User’s Guide. Version 6. 4th ed. SAS Institute Inc, Cary, North Carolina1987
        • Woodhouse P.R
        • Khaw K.T
        • Plummer M
        • et al.
        Seasonal variations of plasma fibrinogen and factor VII activity in the elderly.
        Lancet. 1994; 343: 435-439
        • Bremner W.F
        • Sothern R.B
        • Kanabrocki E.L
        • et al.
        Relation between circadian patterns in levels of circulation lipoprotein (a), fibrinogen, platelets, and related lipid variables in men.
        Am Heart J. 2000; 139: 164-173
        • Yamamoto H
        • Bogousslavsky J
        Mechanisms of second and further strokes.
        J Neurol Neurosurg Psych. 1998; 64: 771-776
        • Kwa V.I.H
        • Franke C.L
        • Verbeeten B
        • et al.
        Silent intracerebral microhemorrhages in patients with ischemic stroke.
        Ann Neurol. 1998; 44: 372-377
        • Petty G.W
        • Brown Jr, R.D
        • Whisnant J.P
        • et al.
        Ischemic stroke subtypes.
        Stroke. 1999; 30: 2513-2516
        • Grotta J.C
        • Yatsu F.M
        • Pettigrew L.C
        • et al.
        Prediction of carotid stenosis progression by lipid and hematologic measurements.
        Neurology. 1989; 39: 1325-1331
        • Levenson J
        • Giral P
        • Razavian M
        • et al.
        Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors.
        Arterioscler Thromb Vasc Biol. 1995; 15: 1263-1268
        • Tomimoto H
        • Akiguchi I
        • Wakita H
        • et al.
        Coagulation activation in patients with Binswanger disease.
        Arch Neurol. 1999; 56: 1104-1108
        • Briley D.P
        • Giraud G.D
        • Beamer N.B
        • et al.
        Spontaneous echo contrast and hemorheologic abnormalities in cerebrovascular disease.
        Stroke. 1994; 25: 1564-1569
        • Binsack R
        • Stegmeier K
        • Dorge L
        • et al.
        Bezafibrate down-regulates fibrinogen biosynthesis in human hepatoma HepG2 cells.
        Eur J Clin Invest. 1998; 28: 151-163
        • Ridker P.M
        Inflammation, infection, and cardiovascular disease.
        Circulation. 1995; 91: 2844-2850
        • Toss H
        • Gnarpe J
        • Gnarpe H
        • et al.
        Increased fibrinogen levels are associated with persistent Chlamydia pneumoniae infection in unstable coronary artery disease.
        Eur Heart J. 1998; 19: 570-577
        • Torgano G
        • Cosentini R
        • Mandelli C
        • et al.
        Treatment of Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma level in patients with ischemic heart disease.
        Circulation. 1999; 99: 1555-1559
        • Mauriello A
        • Sangiorgi G
        • Palmieri G
        • et al.
        Hyperfibrinogenemia is associated with specific histocytological composition and complications of atherosclerotic carotid plaques in patients affected by transient ischemic attacks.
        Circulation. 2000; 101: 744-750